相似文献
1
Emerging insights into the molecular and cellular basis of glioblastoma.
Genes Dev. 2012 Apr 15;26(8):756-84. doi: 10.1101/gad.187922.112.
2
Genomics illuminates a deadly brain cancer.
JAMA. 2010 Mar 10;303(10):925-7. doi: 10.1001/jama.2010.236.
3
Genetics of glioblastoma: a window into its imaging and histopathologic variability.
Radiographics. 2011 Oct;31(6):1717-40. doi: 10.1148/rg.316115512.
4
Established and emerging variants of glioblastoma multiforme: review of morphological and molecular features.
Folia Neuropathol. 2012;50(4):301-21. doi: 10.5114/fn.2012.32361.
5
[Classification of glioblastoma and genome profiling].
Neurochirurgie. 2010 Dec;56(6):464-6. doi: 10.1016/j.neuchi.2010.07.009.
6
Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme.
Proc Natl Acad Sci U S A. 2005 Apr 19;102(16):5814-9. doi: 10.1073/pnas.0402870102. Epub 2005 Apr 12.
7
Classification of glioblastoma multiforme in adults by molecular genetics.
Cancer J. 2003 Mar-Apr;9(2):82-90. doi: 10.1097/00130404-200303000-00003.
8
Molecular Subgroups of Glioblastoma- an Assessment by Immunohistochemical Markers.
Pathol Oncol Res. 2019 Jan;25(1):21-31. doi: 10.1007/s12253-017-0311-6. Epub 2017 Sep 26.
9
Transcriptome profiling-based identification of prognostic subtypes and multi-omics signatures of glioblastoma.
Sci Rep. 2019 Jul 22;9(1):10555. doi: 10.1038/s41598-019-47066-y.
10
Genomics boosts brain-cancer work.
Nature. 2010 Jan 21;463(7279):278. doi: 10.1038/463278a.
引用本文的文献
1
High expression of SOX9 is a diagnostic and prognostic indicator of glioma.
Front Oncol. 2025 Jul 7;15:1531937. doi: 10.3389/fonc.2025.1531937. eCollection 2025.
2
CaMKK2 as a therapeutic target to combat metastasis in glioblastoma.
Mol Biol Rep. 2025 Jul 10;52(1):696. doi: 10.1007/s11033-025-10813-8.
3
Cancer/testis antigens FBXO39 and CEP55 expression correlates with survival in GBM patients.
PLoS One. 2025 Jun 12;20(6):e0326054. doi: 10.1371/journal.pone.0326054. eCollection 2025.
4
Glioblastoma Stem Cells at the Nexus of Tumor Heterogeneity, Immune Evasion, and Therapeutic Resistance.
Cells. 2025 Apr 9;14(8):562. doi: 10.3390/cells14080562.
5
Multi-transcriptomics reveals niche-specific expression programs and endothelial cells in glioblastoma.
J Transl Med. 2025 Apr 15;23(1):444. doi: 10.1186/s12967-025-06185-z.
6
The Co-Expression and Cellular Location of HER Family Members, EGFRvIII, Putative Cancer Stem Cell Biomarkers CD44 and CD109 in Patients with Glioblastoma, and Their Impacts on Prognosis.
Cancers (Basel). 2025 Apr 4;17(7):1221. doi: 10.3390/cancers17071221.
7
Inhibition of glioma cell viability by jatrophone via NF-κB down-regulation and apoptosis inhibitor up-regulation.
Arch Med Sci. 2020 Apr 15;21(1):224-232. doi: 10.5114/aoms.2020.94439. eCollection 2025.
8
Tumor-infiltrating and circulating B cells mediate local and systemic immunomodulatory mechanisms in Glioblastoma.
J Neurooncol. 2025 May;172(3):527-548. doi: 10.1007/s11060-025-04989-z. Epub 2025 Mar 13.
9
Dynamic Monitoring of Circulating Tumor DNA to Predict the Risk of Non In Situ Recurrence of Postoperative Glioma: A Prospective Cohort Study.
Cancer Med. 2025 Mar;14(5):e70733. doi: 10.1002/cam4.70733.
10
Response Assessment in Long-Term Glioblastoma Survivors Using a Multiparametric MRI-Based Prediction Model.
Brain Sci. 2025 Jan 31;15(2):146. doi: 10.3390/brainsci15020146.
本文引用的文献
1
Girdin maintains the stemness of glioblastoma stem cells.
Oncogene. 2017 Jun 29;36(26):3796. doi: 10.1038/onc.2017.17. Epub 2017 Feb 20.
2
IDH mutation impairs histone demethylation and results in a block to cell differentiation.
Nature. 2012 Feb 15;483(7390):474-8. doi: 10.1038/nature10860.
3
Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation.
Nature. 2012 Feb 15;483(7390):484-8. doi: 10.1038/nature10898.
4
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype.
Nature. 2012 Feb 15;483(7390):479-83. doi: 10.1038/nature10866.
5
Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response.
Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):3041-6. doi: 10.1073/pnas.1114033109. Epub 2012 Feb 8.
6
Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas.
Nat Genet. 2012 Jan 29;44(3):251-3. doi: 10.1038/ng.1102.
7
The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma.
Genes Dev. 2011 Dec 15;25(24):2594-609. doi: 10.1101/gad.176800.111.
8
Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.
Oncologist. 2012;17(1):72-9. doi: 10.1634/theoncologist.2011-0386. Epub 2011 Dec 16.
9
An in vivo patient-derived model of endogenous IDH1-mutant glioma.
Neuro Oncol. 2012 Feb;14(2):184-91. doi: 10.1093/neuonc/nor207. Epub 2011 Dec 13.
10
Guanylate binding protein 1 is a novel effector of EGFR-driven invasion in glioblastoma.
J Exp Med. 2011 Dec 19;208(13):2657-73. doi: 10.1084/jem.20111102. Epub 2011 Dec 12.
Zotero 插件